Second Sight Medical To Merge With AstraZeneca-Backed Nano Precision Medical

Second Sight Medical Products Inc EYES will acquire privately-held Nano Precision Medical Inc in an all-stock transaction

  • Second Sight Medical develops implantable visual prosthetics.
  • Under the agreement, Nano Precision Medical will merge with a wholly-owned subsidiary of Second Sight
  • The surviving company Nano Precision Medical will be owned by Second Sight. The newly-formed merged company will focus on developing innovative implants for chronic diseases.
  • The combined company will be under NPM's co-founder, CEO, and Chairman, Adam Mendelsohn.
  • Second Sight will issue approximately 134 million shares and acquire about 23% equity of the combined company. 
  • The transaction is expected to close in Q2 / Q3 of FY22.
  • Nano Precision Medical's lead program, NPM-119, is a near clinical stage GLP-1 receptor agonist developed to treat patients with Type 2 diabetes for up to 6 months with a single, tiny subdermal implant. 
  • The first human trial for NPM-119 is anticipated by late 2022. 
  • Before the merger, Second Sight will provide $8 million to NPM for working capital and speed up pipeline programs. EYES shareholders will join NPM shareholders, including AstraZeneca plc AZN
  • AstraZeneca has been a strategic investor in NPM since 2016.
  • Price Action: EYES shares are trading 8.57% higher at $1.52 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: M&ANewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!